Agios Pharmaceuticals, Inc. (AGIO) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Joining us to discuss Agios Pharmaceuticals' first quarter twenty twenty six financial results and business highlights. You can access the slides for today's call by going to the Investors section of our website, agios.com. Please note we'll be making certain forward looking statements today. Actual events and results could differ materially from those expressed or implied by any forward looking statements because of various risks, uncertainties and other factors, including those set forth in our most recent filings with the SEC and any other future filings that we may make with the SEC. On the call with me today from AGIO are Brian Goff, Chief Executive Officer Cecilia Jones, Chief Financial Officer Sveta Milanova, Chief Commercial Officer and Doctor. Sarah Huynh, Chief Medical Officer and Head of Research and Development. Following prepared remarks, we will open the call for questions. With that, I am pleased to turn the call over to Brian. Thanks, Morgan. Good morning, everyone, and thank you for joining us. Next slide, please. At the start of the year, we outlined our 2026 strategic priorities, which are designed to drive both execution and long term value creation. We are off to a strong start entering another catalyst rich year with clear momentum across these priorities. Turning to first quarter highlights on the next slide, we delivered $20,700,000 in net revenues, representing 138% growth year over year. The first quarter marks The U. S. Commercial launch of ACBESMY in thalassemia with the REMS fully operational as of the end of January. And already, we have shown strong initial demand. We continue to expect 2026 operating expenses to be approximately flat versus 2025. And we ended the quarter with a strong balance sheet, including over $1,000,000,000 in cas...